Robert F. Kennedy Jr. has investments in biotech companies that use gene editing technology he previously cautioned against, his Senate confirmation ethics paperwork revealed Wednesday.
Kennedy holds dividend rights to multiple biotech firms, including a stake in CRISPR Therapeutics, ethics paperwork he filed in his bid to be confirmed as President Donald Trump’s Secretary of Health and Human Services (HHS) revealed.
CRISPR Therapeutics touts a gene editing therapy, a technology which Kennedy has strongly cautioned against, previously warning it can cause cancer.
“Research on CRISPR gene editing for gene therapy applications shows it can lead to massive damage to chromosomes — known as chromothripsis — which can lead to cancer or an inherited disease in any children of the affected patient,” Kennedy wrote in a 2021 post on Facebook.
He also sounded the alarm on Microsoft founder Bill Gates’ use of CRISPR, warning that Gates and the World Economic Forum, both frequent targets of Kennedy’s harsh rhetoric, are prime purveyors of the technology.
Complete Article
Kennedy holds dividend rights to multiple biotech firms, including a stake in CRISPR Therapeutics, ethics paperwork he filed in his bid to be confirmed as President Donald Trump’s Secretary of Health and Human Services (HHS) revealed.
CRISPR Therapeutics touts a gene editing therapy, a technology which Kennedy has strongly cautioned against, previously warning it can cause cancer.
“Research on CRISPR gene editing for gene therapy applications shows it can lead to massive damage to chromosomes — known as chromothripsis — which can lead to cancer or an inherited disease in any children of the affected patient,” Kennedy wrote in a 2021 post on Facebook.
He also sounded the alarm on Microsoft founder Bill Gates’ use of CRISPR, warning that Gates and the World Economic Forum, both frequent targets of Kennedy’s harsh rhetoric, are prime purveyors of the technology.
Complete Article
